FDA has often asked ODAC members to discuss broad scientific questions. However, the approval questions have, without an exception, been shoehorned into the up-or-down dichotomy.
The FDA Oncologic Drugs Advisory Committee July 9 appears to have recommended approval for the Eli Lilly and Co. agent necitumumab.Yes, the word “appears” has indeed appeared in the previous sentence.
Proton Partners International Ltd. acquired the site for the first high energy proton beam therapy cancer treatment center will be built in the U.K.
Mevion Medical Systems delivered a superconducting synchrocyclotron accelerator for its Mevion S250 proton therapy system under installation at University Hospitals Seidman Cancer Center and UH Rainbow Babies & Children's Hospital in Cleveland.
The Leukemia & Lymphoma Society accelerated a portion of the final payment linked to the phase III study of CPX-351 (cytarabine:daunorubicin) liposome injection, Celator Pharmaceuticals' lead product candidate, for the treatment of patients with high-risk acute myeloid leukemia.
CYRUS GHAJAR received a $4.1 million Department of Defense Breast Cancer Research Program “Era of Hope” Scholar Award.
The LIVESTRONG Foundation announced two appointments to its senior leadership: Donna Palmer as chief development officer, and Katie Merrell as vice president of people.
GEORGE WILDING was named vice provost for clinical and interdisciplinary research at MD Anderson Cancer Center. His appointment will begin Sept. 1.
JONATHAN LICHT was appointed director of the University of Florida Health Cancer Center, effective Oct. 1.
The Cancer Letter won a first place 2015 National Press Club Award in the NPC's annual journalism competition June 26.
